Nicolau Beckmann1, Christelle Gerard1, Dorothee Abramowski2, Catherine Cannet1, Matthias Staufenbiel2
1Global Imaging Group,
Novartis Institutes for BioMedical Research,
With about 20 antibodies and vaccines currently in clinical trials amyloid- (A) immunotherapy is the most heavily studied novel treatment approach for Alzheimer's disease (AD). Although generally well tolerated A immunotherapy has been associated with microvascular lesions as indicated clinically by vasogenic edema and histologically by microhemorrhages. In our study we have (i) developed an MRI method based on the administration of superparamagnetic iron oxide (SPIO) nanoparticles to non-invasively study the development of cerebral amyloid angiopathy (CAA) in amyloid precursor protein (APP) transgenic mouse models and (ii) applied the method to a passive A immunotherapy study in APP23 mice.